Pirtobrutinib

Pirtobrutinib (LOXO-305), a highly selective and non-covalent next generation BTK inhibitor, inhibits diverse BTK C481 substitution mutations. Pirtobrutinib causes regression of BTK-dependent lymphoma tumors in mouse xenograft models. Pirtobrutinib is also more than 300-fold selective for BTK versus 370 other kinases tested and shows no significant inhibition of non-kinase off-targets at 1 μM[1].

Product Specifications

CAS Number

[2101700-15-4]

Product Name Alternative

LOXO-305

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Btk

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/btk-inhibitor-16.html

Purity

99.90

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C(C1=C(N)N([C@@H](C)C(F)(F)F)N=C1C2=CC=C(CNC(C3=CC(F)=CC=C3OC)=O)C=C2)N

Molecular Formula

C22H21F4N5O3

Molecular Weight

479.43

Precautions

H302, H315, H319, H335

References & Citations

[1]Gomez E B , et al. Loxo-305, a Highly Selective and Non-Covalent Next Generation BTK Inhibitor, Inhibits Diverse BTK C481 Substitution Mutations[J]. Blood, 2019, 134 (Supplement_1) :4644-4644.